The research team found that participants with genetic makeup mimicking the effect of GLP-1 receptor agonists leads to reductions in both lean mass (whole-body fat-free mass and trunk fat-free mass) and body fat (whole-body fat mass, trunk fat percentage and body fat percentage)
Peptides as therapeutic agents: Challenges and opportunities in the green transition era
However, it is noteworthy that 20% of patients treated with the 2.4 mg dose of pemvidutide discontinued treatment due to adverse events, with nausea and vomiting being the most common AEs
Avoid injecting into areas with scars, bruises, or visible blood vessels
The quality of compounded GLP-1 products may therefore be variable
Even if companies retain the ability to compound under specific conditions, the loss of high-conversion marketing language necessitates a revision of the sales funnel